US Patent Issued to THE UNIVERSITY OF SYDNEY on June 30 for "Adamantanyl-substituted benzamide compounds and their use as P2X 7 receptor antagonists" (Australian Inventors)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,668,568, issued on June 30, was assigned to THE UNIVERSITY OF SYDNEY (Sydney).

"Adamantanyl-substituted benzamide compounds and their use as P2X 7 receptor antagonists" was invented by Michael Kassiou (Lugamo, Australia), Gemma Figtree (Sydney), James O'Brien-Brown (Lane Cove North, Australia), Shane Wilkinson (Sydney) and Thomas Hansen (Greenwich, Australia).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to adamantanyl-substituted benzamide compounds and their use as antagonists of the P2X7 purinoreceptor. The invention further relates to methods for the treatment of disease and conditions associated with the P2X7 purinorec...